This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration. Need a new registration confirmation email? Click here
Sept. 10, 2012 /PRNewswire/ -- 3SBio Inc. (NASDAQ: SSRX) ("3SBio" or "Company"), a leading
China-based biotechnology company focused on researching, developing, manufacturing and marketing biopharmaceutical products, today announced that the 2012 annual general meeting of shareholders will be held on
October 10, 2012 at
Beijing time, at our executive office, 15/A-D, Huaxin International Tower, No. 219, Qingnian Ave., Shenhe District,
People's Republic of China.
Holders of record of ordinary shares of the Company at the close of business on
August 31, 2012 ("Record Date") are entitled to notice of and to vote at the annual general meeting or any adjournment or postponement thereof. Holders of the Company's American depositary shares ("ADSs") who wish to exercise their voting rights for the underlying ordinary shares must act through the depositary of the Company's ADS program, JPMorgan Chase Bank, N.A.
3SBio has filed its annual report on Form 20-F containing the audited financial statements for the fiscal year ended
December 31, 20011 with the U.S. Securities and Exchange Commission (the "SEC"), available on SEC's website at
http://www.sec.gov. 3SBio's annual report on Form 20-F can also be accessed on the Investors section of the Company's website at
http://www.3SBio.com. The materials related to the 2012 annual general meeting, including the notice of meeting, the proxy statement, and the ADR voting card may also be accessed and downloaded at the Investors section of the Company website under the "AGM" heading. Additionally, shareholders may request a hard copy of the above documents free of charge by contacting
About 3SBio Inc.
3SBio is a leading, fully integrated, profitable biotechnology company focused on researching, developing, manufacturing and marketing biopharmaceutical products primarily in China. Its focus is on addressing large markets with significant unmet medical needs in nephrology, oncology, supportive cancer care, inflammation and infectious diseases. With headquarters and GMP-certified manufacturing facilities in
Shenyang, PRC, 3SBio employs over 800 people. Shares trade in the form of American Depositary Shares (ADSs) on the NASDAQ stock market under the ticker symbol "SSRX." Please see
www.3SBio.com for more information.
Investor ContactsBo TanChief Financial Officer3SBio Inc.Tel: + 86 24 2581-1820
ir@3SBio.comTom FolinsbeeDirector of Investor Relations3SBio Inc. Tel: + 852 8191-6991